
Former Voyager CEO Andre Turenne makes a comeback with Atlas-backed covalent drug biotech
Last May, Andre Turenne resigned from his CEO and president posts at Voyager to “pursue other opportunities” after the neuroscience biotech, once one half of major partnerships with Sanofi, AbbVie and Neurocrine, faced one setback after another that put it and its gene therapies out of the clinic — though it’s now staging a comeback with former Biogen R&D chief Al Sandrock at the helm.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.